食管癌新辅助免疫治疗及其CT/MRI评价研究进展的述评  

Review of the research progress in neoadjuvant immunotherapy and CT/MRI evaluation for esophageal cancer

作　　者：陈天武 郭文文 李勇 严高武 CHEN Tianwu;GUO Wenwen;LI Yong;YAN Gaowu(Department of Radiology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China;Department of Radiology,Suining Central Hospital,Suining 629099,Sichuan,China)

机构地区：[1]重庆医科大学附属第二医院放射科,重庆400010 [2]遂宁市中心医院放射影像科,四川遂宁629099

出　　处：《西部医学》2025年第4期477-482,共6页Medical Journal of West China

基　　金：国家自然科学基金面上项目(82271959);四川省医学会科研项目(2024HR125);四川省医学科技创新研究会科研项目(YCH-KY-YCZD2024-164)。

摘　　要：食管癌作为我国最常见的恶性肿瘤之一,是临床及科研工作者的研究热点。食管癌早期症状不典型,因而多数患者在就诊时已处于晚期状态,从而失去宝贵的手术机会。对于晚期食管癌患者,既往临床上常采用综合治疗方案(如化疗、放疗等)以控制肿瘤进展。对于食管癌,新辅助免疫治疗有望改善肿瘤的治疗效果,为患者带来新的曙光。影像学检查在食管癌患者的诊断、疗效评估及随访过程中起到了重要作用,是发展前景良好的检查手段。因此,本文将对食管癌新辅助免疫治疗的研究进展进行阐述并探讨其影像学评估。As one of the most common malignant tumors in our country,esophageal cancer has been the focus of clinical and scientific research.The early symptoms of esophageal cancer are not typical,so most patients are already in an advanced state at the time of treatment,thus losing valuable surgical opportunities.For patients with advanced esophageal cancer,comprehensive treatment programs(such as chemotherapy,radiotherapy,etc.)are often used to control tumor progression in clinical protocol.In recent years,immunotherapy has been widely used in the treatment of various malignant tumors.For esophageal cancer,immunotherapy has gradually become the standard treatment.Neoadjuvant immunotherapy is expected to improve the therapeutic effect of tumor and bring a new dawn for patients.Imaging examination plays an important role in the diagnosis,evaluation of curative effect and follow-up for patients of esophageal cancer,and is a promising examination method.Therefore,this article will discuss the research progress of neoadjuvant immunotherapy for esophageal cancer and discuss its imaging evaluation.

关 键 词：食管癌 新辅助治疗 免疫治疗 影像学 

分 类 号：R735.1[医药卫生—肿瘤]